[81]
On this basis, Apotex argues that if the patent was to be read so widely as to encompass levofloxacin's hemihydrate, it would be invalid since the '840 patent not only disclosed levofloxacin but had already disclosed that its compounds achieved "more excellent antibacterial activity" and "low toxicity". In addition, the '840 patent had disclosed that the compounds of its invention had a high degree of water solubility as it states that these compounds could be administered by injection.